Reaction
Rotavirus Infection reporting signals
As of the last recalculation, Rotavirus Infection appears in 561 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 98.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Palivizumab | 38 | 98.4 | 98.6 |
| Teduglutide | 13 | 36.6 | 36.7 |
| Alemtuzumab | 18 | 35.6 | 35.7 |
| Melphalan | 18 | 30.3 | 30.3 |
| Melphalan Hydrochloride | 18 | 27.5 | 27.5 |
| Busulfan | 11 | 26.4 | 26.5 |
| Sirolimus | 9 | 25.2 | 25.2 |
| Thiotepa | 6 | 23.6 | 23.6 |
| Fludarabine Phosphate | 23 | 22.6 | 22.6 |
| Canakinumab | 5 | 17.3 | 17.3 |
| Vigabatrin | 4 | 10.2 | 10.3 |